Precision treatment for human epidermal growth factor receptor 2- amplified advanced rectal cancer: A case report  

作　　者：Xia Xiao Qing-Wen Wang Zheng-Yang Zhou Lei-Sheng Wang Pei Huang 

机构地区：[1]Department of Oncology,Wuxi No.2 People’s Hospital,Jiangnan University Medical Center,Wuxi 214002,Jiangsu Province,China [2]Wuxi Medical College,Jiangnan University,Wuxi 214122,Jiangsu Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期515-522,共8页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by the Jiangsu Provincial Health and Family Planning Commission Personnel Talent Project,No.R2017005.

摘　　要：BACKGROUND Although targeted therapy provides survival benefits for patients with metastatic colorectal cancer,some patients develop resistance to these treatments.Human epidermal growth factor receptor 2(HER2)is overexpressed in a subset of pa-tients with colorectal cancer and has been established as a therapeutic target.CASE SUMMARY This case report describes a Chinese patient with HER2-amplified advanced rectal cancer who showed no response to chemotherapy and targeted therapies against epidermal growth factor receptor and vascular endothelial growth factor but achieved a remarkable response following treatment with immune checkpoint inhibitors(ICIs)in combination with pyrotinib.The combination of oxaliplatin and ICIs with pyrotinib demonstrates synergistic effects after late-stage disease progression.CONCLUSION ICIs and pyrotinib may be effective in treating HER2-amplified advanced rectal cancer.Chemotherapy following disease progression could enhance efficacy synergistically.

关 键 词：Rectal cancer Human epidermal growth factor receptor 2 Programmed death 1 Pyrotinib CHEMOTHERAPY Case report 

分 类 号：R73[医药卫生—肿瘤]